114 related articles for article (PubMed ID: 26034055)
1. Pacritinib Bests Available Therapies for Myelofibrosis.
Cancer Discov; 2015 Jul; 5(7):OF7. PubMed ID: 26034055
[No Abstract] [Full Text] [Related]
2. The role of pacritinib in the management of myelofibrosis.
Duong VH; Komrokji RS
Expert Rev Hematol; 2014 Jun; 7(3):325-32. PubMed ID: 24746271
[TBL] [Abstract][Full Text] [Related]
3. The development, safety and efficacy of pacritinib for the treatment of myelofibrosis.
Jain T; Mesa R
Expert Rev Anticancer Ther; 2016 Nov; 16(11):1101-1108. PubMed ID: 27598824
[TBL] [Abstract][Full Text] [Related]
4. A comprehensive review of pacritinib in myelofibrosis.
Verstovsek S; Komrokji RS
Future Oncol; 2015; 11(20):2819-30. PubMed ID: 26367195
[TBL] [Abstract][Full Text] [Related]
5. Pacritinib versus best available therapy for the treatment of myelofibrosis irrespective of baseline cytopenias (PERSIST-1): an international, randomised, phase 3 trial.
Mesa RA; Vannucchi AM; Mead A; Egyed M; Szoke A; Suvorov A; Jakucs J; Perkins A; Prasad R; Mayer J; Demeter J; Ganly P; Singer JW; Zhou H; Dean JP; Te Boekhorst PA; Nangalia J; Kiladjian JJ; Harrison CN
Lancet Haematol; 2017 May; 4(5):e225-e236. PubMed ID: 28336242
[TBL] [Abstract][Full Text] [Related]
6. Results of a phase 2 study of pacritinib (SB1518), a JAK2/JAK2(V617F) inhibitor, in patients with myelofibrosis.
Komrokji RS; Seymour JF; Roberts AW; Wadleigh M; To LB; Scherber R; Turba E; Dorr A; Zhu J; Wang L; Granston T; Campbell MS; Mesa RA
Blood; 2015 Apr; 125(17):2649-55. PubMed ID: 25762180
[TBL] [Abstract][Full Text] [Related]
7. Pacritinib: a new agent for the management of myelofibrosis?
Beauverd Y; McLornan DP; Harrison CN
Expert Opin Pharmacother; 2015; 16(15):2381-90. PubMed ID: 26389774
[TBL] [Abstract][Full Text] [Related]
8. Pacritinib: First Approval.
Lamb YN
Drugs; 2022 May; 82(7):831-838. PubMed ID: 35567653
[TBL] [Abstract][Full Text] [Related]
9. Pacritinib to treat myelofibrosis patients with thrombocytopenia.
Tremblay D; Mascarenhas J
Expert Rev Hematol; 2018 Sep; 11(9):707-714. PubMed ID: 30001163
[TBL] [Abstract][Full Text] [Related]
10. Phase 1/2 study of pacritinib, a next generation JAK2/FLT3 inhibitor, in myelofibrosis or other myeloid malignancies.
Verstovsek S; Odenike O; Singer JW; Granston T; Al-Fayoumi S; Deeg HJ
J Hematol Oncol; 2016 Dec; 9(1):137. PubMed ID: 27931243
[TBL] [Abstract][Full Text] [Related]
11. Safety considerations when treating myelofibrosis.
O'Sullivan JM; McLornan DP; Harrison CN
Expert Opin Drug Saf; 2016 Sep; 15(9):1185-92. PubMed ID: 27187785
[TBL] [Abstract][Full Text] [Related]
12. Pacritinib for myelofibrosis in adults with thrombocytopenia.
Yang DH; Lu Q; Zhu Z; Huang G; Young K
Drugs Today (Barc); 2022 Dec; 58(12):577-589. PubMed ID: 36651066
[TBL] [Abstract][Full Text] [Related]
13. Managing side effects of JAK inhibitors for myelofibrosis in clinical practice.
Saeed I; McLornan D; Harrison CN
Expert Rev Hematol; 2017 Jul; 10(7):617-625. PubMed ID: 28571503
[TBL] [Abstract][Full Text] [Related]
14. Long-term treatment with pacritinib on a compassionate use basis in patients with advanced myelofibrosis.
Harrison C; Yacoub A; Scott B; Mead A; Gerds AT; Kiladjian JJ; Mesa R; Egyed M; Scheid C; Gutierrez VG; O'Sullivan J; Buckley S; Kanellopoulos K; Mascarenhas J
Haematologica; 2023 Jul; 108(7):1960-1964. PubMed ID: 36601980
[No Abstract] [Full Text] [Related]
15. Outcomes of patients with myelofibrosis treated with compassionate use pacritinib: a sponsor-independent international study.
Mascarenhas J; Virtgaym E; Stal M; Blacklock H; Gerds AT; Mesa R; Ganly P; Snyder D; Tabbara I; Tremblay D; Moshier E
Ann Hematol; 2018 Aug; 97(8):1369-1374. PubMed ID: 29616317
[TBL] [Abstract][Full Text] [Related]
16. First Approval of Pacritinib as a Selective Janus Associated Kinase-2 Inhibitor for the Treatment of Patients with Myelofibrosis.
De SK
Anticancer Agents Med Chem; 2023; 23(12):1355-1360. PubMed ID: 36959157
[TBL] [Abstract][Full Text] [Related]
17. Pacritinib and its use in myelofibrosis associated thrombocytopenia.
Qureshi FA; Zulfi MH; Abbas Z
J Pak Med Assoc; 2023 Jun; 73(6):1353. PubMed ID: 37427653
[No Abstract] [Full Text] [Related]
18. Long-Term Hematologic Improvement in a Patient With Cytopenic Myelofibrosis Treated With Pacritinib.
Yacoub A; Mesa RA; Oh ST
JCO Precis Oncol; 2023 Jan; 7():e2200523. PubMed ID: 36634298
[No Abstract] [Full Text] [Related]
19. Pacritinib protects dendritic cells more efficiently than ruxolitinib.
Heine A; Wolf AM; Schlaweck S; Daecke SN; Brossart P; Wolf D
Exp Hematol; 2021 Aug; 100():37-40. PubMed ID: 34182006
[TBL] [Abstract][Full Text] [Related]
20. Extramedullary haematopoiesis within hepatic sinusoids of a patient with primary myelofibrosis.
Yamazaki K; Suzuki S; Kawaguchi T
Br J Haematol; 2022 Mar; 196(5):1130. PubMed ID: 34796484
[No Abstract] [Full Text] [Related]
[Next] [New Search]
